Interstitial Lung Disease
NUH is host to the regional centre for interstitial lung disease (ILD) and the national lymphangioleiomyomatosis (LAM) centre, providing care for patients with ILDs from across the East Midlands and nationally for patients with LAM.
Interstitial lung diseases (ILDs) affect mainly the lung tissue (parenchyma) and include idiopathic pulmonary fibrosis, asbestosis, sarcoidosis, connective tissue disease related lung diseases and hypersensitivity pneumonitis as well as rarer interstitial lung diseases including LAM.
Idiopathic pulmonary fibrosis (IPF) is the most common and most serious of the ILDs, affecting approximately 5,000 people in the UK. It leads to progressive shortness of breath which is not usually noticeable at rest but severely limits any exertion such as walking very short distances. It also leads to a debilitating dry cough.
Through the NIHR Nottingham Biomedical Research Centre, we are increasing our knowledge and understanding of respiratory diseases. Our research is designed to translate research results into new drugs, therapies and treatments to improve the care we can offer to patients.